Aktie 3176 MEDIGEN BIOTECHNOLOGY CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Medigen Biotechnology Corp.

Aktien

3176

TW0003176004

3176

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 03.05.2024 		% 5 Tage % 1. Jan.
39,2 TWD +0,26 % Intraday Chart für Medigen Biotechnology Corp. +1,42 % -12,50 %
29.03. Ministerium für Gesundheit und Soziales genehmigt gemeinsames Projekt zur autologen Gamma-Delta-T-Zelltherapie von Medigen Biotechnology Corp. und Chi Mei Hospital CI
15.03. Medigen Biotechnology Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
The Ministry of Health and Welfare Approves Collaborative Autologous Gamma-Delta T Cell Therapy Project by Medigen Biotechnology Corp. and Chi Mei Hospital
Taiwan MOHW Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by Medigen Biotechnology Corp. and Changhua Christian Hospital
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer
Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK)
Medigen Biotechnology Corp. Announces That the Ministry of Health and Welfare Has Approved the Collaborative Autologous Gamma-Delta T Cell Therapy Project by the Company and Changhua Christian Hospital
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan
The Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi Hospital
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2020
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 3176 Aktie
  4. Nachrichten Medigen Biotechnology Corp.
  5. Andere Sprachen